Alina Vrinceanu-Hamm, MD
Psychiatry · Princeton, WVNPI 1790729028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 254 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$660
- Teva Pharmaceuticals USA, Inc.$654
- Lundbeck LLC$557
- AbbVie$422
- Avanir Pharmaceuticals, Inc.$315
- Alkermes, Inc.$263
- plus $1K from 13 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$4,04793%
- Education$2857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $660 |
| Teva Pharmaceuticals USA, Inc. | 32 | $654 |
| Lundbeck LLC | 31 | $557 |
| AbbVie(2 entities) | 32 | $422 |
| Avanir Pharmaceuticals, Inc. | 21 | $315 |
| Alkermes, Inc. | 13 | $263 |
| Otsuka America Pharmaceutical, Inc. | 15 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $191 |
| Neurocrine Biosciences, Inc. | 10 | $169 |
| Vanda Pharmaceuticals Inc. | 7 | $166 |
| Braeburn Inc. | 7 | $152 |
| Sunovion Pharmaceuticals Inc. | 14 | $127 |
| Axsome Therapeutics, Inc. | 5 | $116 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $99 |
| Indivior Inc. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Corium, LLC | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $25 |
| Eisai Inc. | 1 | $14 |
How this compares
$4,332 in reported general payments places this provider in the 80th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 31 | $107,378 |
| IngrezzaValbenazine Tosylate | 11 | $92,903 |
| VraylarCariprazine Hcl | 25 | $34,845 |
| Lurasidone Hcl | 85 | $15,523 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 198 | $14,166 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 63 | $9,235 |
| Clozapine | 139 | $8,524 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,795 |
| Ziprasidone Hcl | 118 | $5,603 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,340 |
| BelsomraSuvorexant | 12 | $5,191 |
| Hydroxyzine Pamoate | 239 | $3,025 |
| Quetiapine Fumarate | 242 | $2,833 |
| Buspirone Hcl | 310 | $2,641 |
| Aripiprazole | 72 | $2,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $660 | $107,37831 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $169 | $92,90311 claims |
| AbbVieVraylar | $422 | $34,84525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $191 | $13,13530 claims |
| Indivior Inc.Suboxone | $79 | $9,23563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Princeton
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$173K
- Shahnoor KhanMartinsburg$161K
- Ahmed FaheemBeckley$82K
- Steve CorderWheeling$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.